Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given an average rating of “Hold” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $31.8333.

Several equities analysts have weighed in on the company. Wedbush reissued a “neutral” rating and issued a $100.00 target price (up previously from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Wall Street Zen downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd.

Institutional Trading of Sutro Biopharma

Hedge funds have recently added to or reduced their stakes in the business. State of Tennessee Department of Treasury acquired a new position in Sutro Biopharma in the fourth quarter valued at about $86,000. Jane Street Group LLC bought a new position in shares of Sutro Biopharma during the 4th quarter valued at about $265,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Sutro Biopharma during the 2nd quarter valued at about $27,000. Bridgeway Capital Management LLC increased its position in shares of Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Savant Capital LLC bought a new stake in shares of Sutro Biopharma in the second quarter valued at about $37,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Down 5.8%

STRO stock opened at $18.42 on Friday. Sutro Biopharma has a twelve month low of $5.23 and a twelve month high of $19.90. The company has a market cap of $156.75 million, a P/E ratio of -0.71 and a beta of 1.55. The business’s fifty day moving average is $13.43 and its 200-day moving average is $10.58.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.